Bone Marrow Transplant (BMT)
Conditions
Keywords
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Lymphomas, Chronic lymphoblastic Leukemia, Chronic Myeloid Leukemia, myelodysplastic syndrome, stem cell transplant, severe aplastic anemia, Sickle cell anemia, Thalessemia
Brief summary
Ossium recognizes that not all patients who could benefit from Ossium's HPC, Marrow can access the PRESERVE trial for logistical or eligibility reasons. The HOPE program is expanded access program to serve these patients by providing our bone marrow product
Interventions
OTHERBone Marrow Transplant with Ossium's HPC, Marrow (bone marrow recovered from deceased organ and tissue donors)
The HOPE Program does not include any investigational drugs. The medicines and procedures in this program are standard of care for a transplant. Bone marrow cells from a deceased organ and tissue donor for use in your transplant is the only product offered to you by Ossium Health.
Sponsors
Ossium Health, Inc.
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
12 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
Patients aged 12-80 may be eligible\* to receive bone marrow for transplantation through the Ossium HOPE Program if: Their treating physician determined they are eligible for allogeneic bone marrow transplant Their treating physician determined that the potential benefit outweighs the potential risks
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Neutrophil engraftment | 28 days | 1\. To determine cumulative incidences of neutrophil engraftment (ANC ≥500/µL for 3 consecutive values) |
Countries
United States
Contacts
Primary ContactPreethi Prasad, Senior Director Clinical Operations
Outcome results
None listed